ITF Therapeutics was established in January 2024 as the United States affiliate of Italfarmaco Group to develop and commercialize treatments for rare diseases. With deep expertise across regulatory, commercial operations, access, and community partnerships, we are focused on delivering proven therapies with urgency, ambition, and compassion to each rare disease community we serve.